版本:
中国

BRIEF-Kamada provides update on clinical program for alpha-1 antitrypsin IV treatment

June 7 Kamada Ltd

* Provides update on clinical program for alpha-1 antitrypsin IV for treatment of graft-versus-host disease

* Kamada, Shire agreed INDA approved by U.S. FDA for phase 2/3 study evaluating alpha-1 antitrypsin for treatment of GVHD will be transferred to Kamada

* Kamada will take full ownership and responsibility for clinical development of g1-aat iv in this indication

* Kamada Ltd says Shire decided to transfer INDA to Kamada due to pipeline prioritization and slow recruitment rate in its current u.s. Study

* Kamada will assume control of, and onward funding for full G1-AAT iv program

* Kamada Ltd says intends to conduct an integrated clinical development program across both territories - u.s. And eu

* Kamada Ltd says as result of this decision, current part 1 of phase 2/3 study conducted in u.s. Is being halted by shire Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐